Table 2 Response rates
From: A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer
Response | No of patients (%) |
|---|---|
Complete response | 4 (16) |
Partial response | 12(48) |
Overall response | 16(64) |
Stable disease | 5 (20) |
Progressive disease | 4(16) |